Drug Discovery & Pharmaceuticals

RSS

MaxCyte joins the Alliance for mRNA Medicines (AMM) as a founding member

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced that it has joined the Alliance for mRNA Medicines (AMM), as a founding member.

From MaxCyte, Inc. 16 Nov 2023

Novel cancer immunotherapy compound degrades an enzyme found in cancer cells and T cells

Researchers in Purdue University's College of Pharmacy are leveraging the dual roles played by an enzyme found in both cancer cells and T cells to create a novel cancer immunotherapy compound.

14 Nov 2023

Discovery of two new enzymes offers easier ways to study and manufacture complex natural chemicals

Slumbering among thousands of bacterial strains in a collection of natural specimens at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, several fragile vials held something unexpected, and possibly very useful.

13 Nov 2023

New hope for TB patients as UNITE4TB launches clinical trial program

Today, UNITE4TB, an international public-private partnership striving to fast-track the development of innovative Tuberculosis (TB) treatments, announced the start of its phase 2B/C clinical trial program with the first participant enrolled at its trial site in Cape Town, South Africa.

13 Nov 2023

Crown Bioscience launches large-scale organoid panel screening platform for accelerated preclinical oncology drug discovery

Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, today announced the launch of its ground-breaking service offering, OrganoidXploreTM.

13 Nov 2023

New benchmark of solid-solid free energy differences paves way for better pharmaceutical design

Physical properties (stability, solubility, etc.), critical to the performance of pharmaceutical and functional materials, are known to strongly depend on the solid-state form and environmental factors, such as temperature and relative humidity.

10 Nov 2023

Genetically engineered yeast cells produce natural plant product for schizophrenia treatment

An international team of researchers has demonstrated that genetically engineered yeast cells can produce the natural plant product alstonine, which has shown positive effects in treating schizophrenia.

10 Nov 2023

Scientists discover kidney-friendly antifungal that evades resistance

In this investigation, researchers produced powerful antifungals of the polyene class without nephrotoxicity.

9 Nov 2023

Synthetic melanin nanoparticles boost wound healing and tissue repair in skin

In a recent study published in npj Regenerative Medicine, researchers discuss the ability of melanin nanoparticles to support wound recovery in mice. The effects at histological and gene levels were explored and confirmed on biomimetic models and human skin explants.

5 Nov 2023

TUM start-up nominated for Science Breakthrough of the Year at Falling Walls summit

It all began with basic research: While conducting laboratory experiments, a team at the Technical University of Munich (TUM) came across an active agent against multidrug-resistant bacteria with a fundamental difference to antibiotics developed to date.

2 Nov 2023

Industry & academia combine to support synthesis of squaric acid monoamides as building blocks for drug discovery

Global sustainable laboratory equipment visionaries, Asynt, have collaborated with Kingston University (London, UK) and renowned worldwide chemical products supplier, Key Organics, to develop an accessible new synthetic compound library.

From Asynt 2 Nov 2023

Bridging Chemistry and Biology: The Art of Designing Novel Therapeutics

In this interview, we delve into the journey and research of Sona Krajcovicova, exploring how diverse interests led to a passionate pursuit of chemistry, innovative approaches to drug development, and a commitment to making a meaningful impact on the world of therapeutics.

From ELRIG (UK) Ltd. 2 Nov 2023

Proof-of-concept study holds promise for safer gene therapy techniques for treating immunodeficiencies

Researchers described an approach to edit the recombination-activating gene 2 (RAG2) locus for therapeutic applications.

1 Nov 2023

Speeding up Alzheimer's research: Progerin turbocharges cellular models for quicker drug screening

The study reveals that introducing progerin, a protein associated with accelerated aging, into cellular models of Alzheimer's Disease (AD) can hasten the development of AD-related traits. This innovative approach offers a more efficient method for studying AD mechanisms, potentially accelerating the discovery of new treatments.

31 Oct 2023

How next-gen sequencing is changing antibody drug discovery

New study outlines how next-generation sequencing (NGS) and machine-learning methods can revolutionize antibody discovery, particularly against SARS-CoV-2. The research demonstrates that NGS provides greater epitopic and paratopic diversity, enabling more effective identification and prioritization of therapeutic antibodies.

31 Oct 2023

UQ's drug discovery facility opens to researchers nationwide after $1.9M funding injection

The University of Queensland's small molecule drug discovery facility will open its doors to researchers from across Australia for the first time thanks to a National Collaborative Research Infrastructure Strategy (NCRIS) funding injection.

30 Oct 2023

Receptor structure-based virtual screening identifies a promising p38α inhibitor

Announcing a new publication for Acta Materia Medica journal. Mitogen-activated protein kinases (MAPKs) are a group of serine-threonine protein kinases that can be activated by extracellular stimuli.

27 Oct 2023

AI-designed drug candidate shows promise for gastric acid inhibition

Researchers at Nagoya University in Japan created and improved artificial intelligence (AI) designs to synthesize a candidate compound for a new gastric acid inhibitor with a better binding affinity than existing drugs.

26 Oct 2023

MuTaLig: A multi-target paradigm for innovative drug discoveries

Everyone at some point in their life may need to take medication to treat an illness or disease. By finding new and better ways to create drugs, the COST Action Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig) helped improve the effectiveness and safety of the medications, which can ultimately benefit people's health and well-being.

19 Oct 2023

Researchers profile new drug combinations to fight antibiotic-resistant bacteria

Antimicrobial resistance – occurring when pathogens can survive antibiotic treatment – is one of the most rapidly emerging global public health threats today.

19 Oct 2023

Drug Discovery & Pharmaceuticals

MaxCyte joins the Alliance for mRNA Medicines (AMM) as a founding member

Novel cancer immunotherapy compound degrades an enzyme found in cancer cells and T cells

Discovery of two new enzymes offers easier ways to study and manufacture complex natural chemicals

New hope for TB patients as UNITE4TB launches clinical trial program

Crown Bioscience launches large-scale organoid panel screening platform for accelerated preclinical oncology drug discovery

New benchmark of solid-solid free energy differences paves way for better pharmaceutical design

Genetically engineered yeast cells produce natural plant product for schizophrenia treatment

Scientists discover kidney-friendly antifungal that evades resistance

Synthetic melanin nanoparticles boost wound healing and tissue repair in skin

TUM start-up nominated for Science Breakthrough of the Year at Falling Walls summit

Industry & academia combine to support synthesis of squaric acid monoamides as building blocks for drug discovery

Bridging Chemistry and Biology: The Art of Designing Novel Therapeutics

Proof-of-concept study holds promise for safer gene therapy techniques for treating immunodeficiencies

Speeding up Alzheimer's research: Progerin turbocharges cellular models for quicker drug screening

How next-gen sequencing is changing antibody drug discovery

UQ's drug discovery facility opens to researchers nationwide after $1.9M funding injection

Receptor structure-based virtual screening identifies a promising p38α inhibitor

AI-designed drug candidate shows promise for gastric acid inhibition

MuTaLig: A multi-target paradigm for innovative drug discoveries

Researchers profile new drug combinations to fight antibiotic-resistant bacteria

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest Life Science News